Page 2 - Best Oncological Check-up for Women doctors: TOP 61 doctors

Professor Dan Grisaro is a leading Israeli specialist in gynecological cancer diagnosis and treatment, specializing in ovarian cancer, uterine cancer, and cervical cancer. He has senior physician, head of department and lecturer experience at various medical centers and universities. He has held 39 presentations and is the author of 83 published scientific articles, and is a member of various professional societies.

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

Dr. Séverine Iborra is the Chief Physician of the Department of Gynecology and Obstetrics at Städtisches Klinikum Solingen. Her responsibilities include obstetrics, the delivery room, the neonatal unit, and gynecology. The department also includes the Senology/Breast Clinic at the Bergisches Breast Center Solingen, led by Dr. Manuela Seifert.

Dr. Séverine Iborra is originally from France. She began her medical studies at the University of Lyon and later transferred to Albert-Ludwigs University in Freiburg, where she received her medical license in 2007. She earned her doctorate in 2008 for experimental research in molecular oncology. From August 2008 to November 2013, Dr. Iborra worked as a resident at the University Women’s Clinic in Freiburg. After passing her specialist exams in gynecology and obstetrics, she continued her career as a specialist at the same clinic. In November 2015, she moved to RWTH University Hospital Aachen as a senior physician.

At the Clinic for Gynecology and Obstetrics, under the leadership of Prof. Dr. E. Stickeler, Dr. Iborra led the obstetrics department from 2017 to 2019. Since December 2017, she was responsible for organizing education in the department, and in October 2019, she became the Managing Senior Physician and Personnel Senior Physician of the clinic, a position she held until she moved to Solingen.

In addition to her scientific work, with numerous publications and presentations at major gynecological conferences, Dr. Iborra deepened her medical specialties. She obtained certifications in oncological diagnostics and therapy from the Gynecological Oncology Working Group, as well as additional qualifications in Cervical Pathology and Colposcopy (AGCPC), Urogynecology and Pelvic Reconstructive Surgery (AGUP), and the Professional Association of Gynecologists (BVF).

In 2019, Dr. Iborra successfully completed further specialization in “Gynecological Oncology” and “Special Obstetrics and Perinatal Medicine.” She is an active member of leading German medical societies in her field, including the German Society for Gynecology and Obstetrics, the Cervical Pathology and Colposcopy Working Group, and the German Society for Prenatal and Birth Medicine.

Treatments Offered in Our Gynecology Department

• Hysteroscopy and Dilation and Curettage (D&C) for diagnostic and therapeutic purposes.
• Removal of abnormal or symptomatic ovarian findings, such as cysts, while preserving the remaining ovary.
• Oophorectomy (removal of ovaries) in cases of abnormalities or preventively when indicated.
• Myomectomy (removal of uterine fibroids) while preserving the uterus.
• Conservative treatment of fibroids: either medication or embolization performed by radiology specialists.
• Hysterectomy with or without removal of the cervix.
• Diagnosis and clarification of unclear findings in the cervix, vagina, and vulva.
• Dysplasia treatment.
• Endometriosis management.
• Cancer treatment for vulvar, vaginal, cervical, uterine, and ovarian cancers.
• Treatment for incontinence and/or pelvic organ prolapse.

Whenever possible, we offer all procedures as minimally invasive treatments using laparoscopy or the Da Vinci robotic system.

Dr. Victor Alexander Krol - Chief of Gastroenterology, Internal Medicine and Obesity Treatment Center at Martinus Hospital

Dr. Victor Alexander Krol is a highly qualified specialist, heading the departments of gastroenterology and internal medicine. With many years of experience and deep knowledge in his field, Dr. Krol has established himself as an outstanding expert, providing patients with comprehensive treatment and an individual approach. He actively uses the latest methods of diagnosis and treatment of diseases of the gastrointestinal tract, metabolism, as well as diseases of the cardiovascular and respiratory systems.

Dr. Krol is also the director of the certified Obesity Treatment Center at Martinus Hospital, which provides surgical and endoscopic treatments for obesity. The center uses advanced technology to diagnose and treat obesity (adiposis), including methods such as bariatric surgery, endoscopic weight loss, and specialized programs for patients with different stages of obesity. The center is certified to high standards and has excellent results in the treatment of this serious disease.

The Gastroenterology Department, headed by Dr. Krol, diagnoses and treats diseases of the stomach, intestines, liver, pancreas, and gallbladder. The doctors of the department use a wide range of methods, including endoscopic procedures, ultrasound, and other modern diagnostic technologies.

The Department of Internal Medicine covers a wide range of diseases, including cardiology, diabetology, infectology, and therapy of respiratory and renal diseases. Dr. Krol and his team provide a comprehensive approach to treatment using the most advanced methods of medicine.

Thanks to his high professionalism and humane approach to each patient, Dr. Krol deservedly enjoys the respect of colleagues and patients.

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

EDUCATION AND ADVANCED TRAINING COURSES

• 1989 - received higher medical education at the Hebrew University;
• 1995 - completed residency in internal medicine and gastroenterology at the Hadassah University Hospital.
• 2001 - 2002 - Internship with Professor Scott Friedman in the Department of Liver Diseases at Sinai School of Medicine in New York.

Today, Professor Rifaat Safadi is an outstanding specialist in the field of liver disease treatment, a member of the committee for the development of the somatic cell transplant center and the head of the liver disease unit at Hadassah Medical Center. The professor is a member of several international associations for the study of the liver and is the author of numerous articles in his specialty. Professor Safadi is a member of the editorial board of the scientific medical journal Clinical Science.

Rifaat Safadi is a laureate of many scientific awards. In particular, he has been repeatedly awarded the Hadassah Prize for studying the process of immune modulation of liver fibrosis using mRNA. For achievements in the same field, the professor received the Sharon Donsky and the Israeli Association of Gastroenterology and Hepatology awards.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education 

2002 Haydarpaşa Numune Training and Research Hospital, Internal Medicine 

1990 Erciyes University, Faculty of Medicine 

Experience 

2019 - 2019 Okan University Hospital 

2018 - 2019 Ibn Sina Hospital 

2003 - 2018 Pendik State Hospital 

1997 - 2003 Haydarpasa Numune Hospital 

1990 - 1994 Erzincan State Hospital 

Istanbul Haydarpasa Numune Hospital 

Kartal Health Group Presidency 

Yıldırım Beyazıt Mother and Child Health Physician 

Dr. Ersin Öztürk, M.D., is a Professor of Medicine and an expert in General Surgery. His specialties include Surgical Oncology, Gastrointestinal and Laparoscopic Surgery, Obesity Surgery, Hernia Surgery, and Proctology. He holds a Ph.D. in Physiology. Dr. Öztürk completed his residency at Uludağ University and later conducted advanced research at the Cleveland Clinic Foundation in the USA.

He is currently a Professor at Medicana Bursa Hospital. Dr. Öztürk has also served as Assistant and Associate Professor at Uludağ University and as Professor at KTO Karatay University. He is known for his important work in surgical innovation and medical education in Turkey.

Dr. Kayihan Engin is a Radiation Oncologist. He earned his medical degree from Uludağ University Medical College in 1983. He completed his residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. From 1990 to 1994, he pursued a post-doctoral fellowship in Thermoradiotherapy at Thomas Jefferson University in the USA.

Dr. Engin has held key academic and leadership roles. He served as Professor, Chairman, and Faculty Accreditation Coordinator at Uludağ University Medical College from 1991 to 2005. He was also Professor and Director at Anadolu Medical Center between 2004 and 2017. Since 2017, he has led the Oncological Sciences departments at Ceylan International and Medicana Bursa Hospitals. Dr. Engin is known for his work in improving cancer treatment and medical education standards in Turkey.

Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

Dr. Ahmer Arif Shaikh, MDS (Oral & Maxillofacial Surgery), is a specialist in Surgical Oncology. He has 3 years of experience at HCG Manavata Cancer Centre, Nashik. He focuses on oral cancer treatment, organ preservation, and functional rehabilitation for oral cancer patients.

Dr. Shaikh has completed a Fellowship in Head & Neck Surgical Oncology. He is skilled in complex maxillofacial and head & neck surgeries. He is also an active researcher with several publications in reputed journals. His work shows a strong commitment to improving cancer care.

Dr. Lalit Banswal is an experienced oncological surgeon with 10 years in the field. He has performed more than 10,000 major surgeries. He earned his MBBS from MIMER, Pune, and completed his MS at GMC Panaji. He also completed a fellowship in Surgical Oncology at Tata Medical Centre, Kolkata, with a focus on gastrointestinal cancers.

Dr. Banswal has worked as a Co-principal Investigator in several research projects. He has published his work in both national and international journals. He is known for his patient-friendly and ethical approach. His main expertise is in Minimal Invasive Cancer Surgeries, where he consistently delivers excellent results.

Dr. Shaunak Valame is an MD in Internal Medicine and holds a DNB in Medical Oncology. He received advanced training at Indraprastha Apollo Hospital in New Delhi. He also worked as a Registrar at Jawaharlal Nehru Cancer Hospital in Bhopal. Dr. Valame has presented his research at international forums, including the Gastrointestinal Cancer Symposium in San Francisco.

He is known for his work in targeted cancer therapies. He has given lectures at the International Winter School of Oncology at AIIMS Bhopal. Dr. Valame is accredited by the American Society of Clinical Oncology. He is committed to advancing cancer research and clinical care.